Analysts have been eager to weigh in on the Services sector with new ratings on Clean Harbors (CLH), Booking Holdings (BKNG) and Adaptive Biotechnologies (ADPT).
Clean Harbors (CLH)
In a report released today, James Ricchiuti from Needham reiterated a Buy rating on Clean Harbors, with a price target of $110.00. The company’s shares closed last Wednesday at $93.78, close to its 52-week high of $96.19.
According to TipRanks.com, Ricchiuti is a 5-star analyst with an average return of 22.4% and a 65.2% success rate. Ricchiuti covers the Technology sector, focusing on stocks such as Benchmark Electronics, Teledyne Technologies, and Faro Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clean Harbors with a $98.75 average price target, a 9.6% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $95.00 price target.
See today’s analyst top recommended stocks >>
Booking Holdings (BKNG)
In a report released yesterday, Jake Fuller from BTIG maintained a Hold rating on Booking Holdings. The company’s shares closed last Wednesday at $2337.92, close to its 52-week high of $2516.00.
Fuller has an average return of 16.2% when recommending Booking Holdings.
According to TipRanks.com, Fuller is ranked #529 out of 7493 analysts.
Booking Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $2566.14, which is a 6.8% upside from current levels. In a report issued on April 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $2400.00 price target.
Adaptive Biotechnologies (ADPT)
In a report released today, Mark Massaro from BTIG reiterated a Buy rating on Adaptive Biotechnologies, with a price target of $60.00. The company’s shares closed last Wednesday at $35.46, close to its 52-week low of $31.56.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 27.0% and a 63.9% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Talis Biomedical, Exact Sciences, and NeoGenomics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptive Biotechnologies with a $61.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADPT:
